Meeting News

Obesity increases risk for surgery in patients with ulcerative colitis

Amanda M. Lynn
Amanda M. Lynn

Patients with ulcerative colitis who have a higher BMI are at increased risk for bowel resection, according to research presented at the Crohn’s & Colitis Congress.

Amanda M. Lynn, MD, gastroenterology and hepatology fellow at the Mayo Clinic, and colleagues tested obesity as a proposed factor for adverse outcomes in inflammatory bowel disease (IBD). They found that patients with ulcerative colitis (UC) and Crohn’s disease (CD) did not have similar outcomes regarding risk for surgery.

“There is a growing prevalence of obesity within the IBD population, a shift from the historical belief that IBD patients are plagued with weight loss and cachexia,” Lynn told Healio Gastroenterology and Liver Disease. “However, little is known about the effects this has on the natural history of disease.”

Lynn and colleagues used data from the Rochester Epidemiology Project to identify patients diagnosed with IBD and reviewed records for BMI at diagnosis and future IBD-related outcomes.

The study comprised 488 patients, including 221 with CD (45.3%) and 267 with UC (54.7%). The overall prevalence of overweight was 32.4% and 24% for obesity. The researchers stratified outcomes based on incremental increases in BMI by 1 kg/m².

Lynn and colleagues found that with each incremental increase in BMI, patients with UC saw a 6% increased risk for surgery (HR = 1.06; 95% CI, 1.01–1.12), while patients with CD saw their risk for surgery decrease by 5% (HR = 0.95; 95% CI, 0.91–0.99).

“These findings suggest that a higher BMI may be protective in Crohn’s disease and a risk factor for ulcerative colitis patients in terms of future surgery,” Lynn said. “As obesity becomes more pervasive in this population, further investigation of the effects it has on IBD-related outcomes will become increasingly important to allow for better counseling and risk stratification of these patients.” – by Alex Young

Reference: Lynn AM, et al. Abstract P211; Presented at: Crohn’s & Colitis Congress; Jan. 19-20; Last Vegas, NV.

Disclosures: Lynn reports no relevant financial disclosures.

Amanda M. Lynn
Amanda M. Lynn

Patients with ulcerative colitis who have a higher BMI are at increased risk for bowel resection, according to research presented at the Crohn’s & Colitis Congress.

Amanda M. Lynn, MD, gastroenterology and hepatology fellow at the Mayo Clinic, and colleagues tested obesity as a proposed factor for adverse outcomes in inflammatory bowel disease (IBD). They found that patients with ulcerative colitis (UC) and Crohn’s disease (CD) did not have similar outcomes regarding risk for surgery.

“There is a growing prevalence of obesity within the IBD population, a shift from the historical belief that IBD patients are plagued with weight loss and cachexia,” Lynn told Healio Gastroenterology and Liver Disease. “However, little is known about the effects this has on the natural history of disease.”

Lynn and colleagues used data from the Rochester Epidemiology Project to identify patients diagnosed with IBD and reviewed records for BMI at diagnosis and future IBD-related outcomes.

The study comprised 488 patients, including 221 with CD (45.3%) and 267 with UC (54.7%). The overall prevalence of overweight was 32.4% and 24% for obesity. The researchers stratified outcomes based on incremental increases in BMI by 1 kg/m².

Lynn and colleagues found that with each incremental increase in BMI, patients with UC saw a 6% increased risk for surgery (HR = 1.06; 95% CI, 1.01–1.12), while patients with CD saw their risk for surgery decrease by 5% (HR = 0.95; 95% CI, 0.91–0.99).

“These findings suggest that a higher BMI may be protective in Crohn’s disease and a risk factor for ulcerative colitis patients in terms of future surgery,” Lynn said. “As obesity becomes more pervasive in this population, further investigation of the effects it has on IBD-related outcomes will become increasingly important to allow for better counseling and risk stratification of these patients.” – by Alex Young

Reference: Lynn AM, et al. Abstract P211; Presented at: Crohn’s & Colitis Congress; Jan. 19-20; Last Vegas, NV.

Disclosures: Lynn reports no relevant financial disclosures.

    See more from Crohn's & Colitis Congress